Surgical Applications

Patient Identification

Which Patients Should be Considered for a Surgically-Inserted Impella® Heart Pump?

  • Significant hemodynamic deficit
  • Potential need to escalate support

Why Escalate?

  • Unload the left ventricle
  • Increase end organ perfusion
  • Facilitate ambulation with axillary insertion of Impella 5.0® or Impella 5.5® with SmartAssist® heart pumps

Download Clinical Dossier

Learn more about key findings from RECOVER I and other ongoing clinical trials.

Best Practices in Cardiogenic Shock

Recently published studies have shown that implementing AMICS best practices can influence patient survival.1, 2, 3, 4

  • Early detection of cardiogenic shock and use of the Impella® heart pump prior to PCI within 90 minutes of the onset of shock

  • Aggressive down-titration of inotropes
  • Early detection and support of right ventricular dysfunction
  • Identification and escalation in the case of inadequate left ventricular support
  • Systematic use of right heart catheters to guide therapy

The Interdisciplinary Shock Team Are the Key to the Best Possible Clinical Outcome in Cardiogenic Shock

Early diagnosis, stabilisation, revascularisation and assessment of cardiac recovery are required in patients with cardiogenic shock. Protocols are increasingly being developed in facilities across the US and some hospitals have developed coordinated strategies, including the establishment of shock teams. These structures are being developed to represent best practices in trauma, STEMI and acute pulmonary embolism care. Shock teams should be multidisciplinary in structure and fully informed of the resources that the hospital can provide. If the hospital cannot offer early revascularisation for patients with cardiogenic shock, rapid transfer to a facility that can offer early revascularisation is recommended.

 

What Escalation Strategies Can Increase Unloading?

Cardiothoracic surgeon Mark Anderson, MD, discussed how cardiac surgery can help bring the survival rate closer to the quality measure of ≥ 80% survival to discharge, as shown in the National Cardiogenic Shock Initiative (NCSI) study.

 

Any New Solutions in Structural Heart Disease Using pMCS?

PD Schmack (Germany) explained that Impella can also give support in other indications than CS, e.g. in structural heart disease of mitral regurgitation, due to the overestimation of LV function.

Education Library

Discover additional videos and resources in our education library.

References

  1. Tehrani BN, Truesdell AG, Sherwood MW, et al. Standardized team-based care for cardiogenic shock. J Am Coll Cardiol. 2019;73(13):1659-1669.
  2. O’Neill W. Achieving >70 % AMI-CS Survival: Best Practices from Around the World. Proceedings of the TCT Connect 2020 Oct 14-18 (Online); USA
  3. Basir B, et al. SCAI Scientific Session 2021.
  4. Sawa Y. Japanese Circulation Society, Kyoto. 2020.

NPS-2616